Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology
Creators
- 1. Corresponding address: 420 Delaware St SE MMC 715, Minneapolis, MN 55455 (United States)
- 2. Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455 (United States)
- 3. Division of Pediatric Epidemiology and Clinical Research, University of Minnesota, Minneapolis, MN 55455 (United States)
- 4. Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN 55455 (United States)
- 5. Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455 (United States)
- 6. Stem Cell Institute, University of Minnesota, Minneapolis, MN 55455 (United States)
Description
Alterations in methylation patterns, miRNA expression, and stem cell protein expression occur in germ cell tumors (GCTs). Our goal is to integrate molecular data across platforms to identify molecular signatures in the three main histologic subtypes of Type I and Type II GCTs (yolk sac tumor (YST), germinoma, and teratoma). We included 39 GCTs and 7 paired adjacent tissue samples in the current analysis. Molecular data available for analysis include DNA methylation data (Illumina GoldenGate Cancer Methylation Panel I), miRNA expression (NanoString nCounter miRNA platform), and stem cell factor expression (SABiosciences Human Embryonic Stem Cell Array). We evaluated the cross platform correlations of the data features using the Maximum Information Coefficient (MIC). In analyses of individual datasets, differences were observed by tumor histology. Germinomas had higher expression of transcription factors maintaining stemness, while YSTs had higher expression of cytokines, endoderm and endothelial markers. We also observed differences in miRNA expression, with miR-371-5p, miR-122, miR-302a, miR-302d, and miR-373 showing elevated expression in one or more histologic subtypes. Using the MIC, we identified correlations across the data features, including six major hubs with higher expression in YST (LEFTY1, LEFTY2, miR302b, miR302a, miR 126, and miR 122) compared with other GCT. While prognosis for GCTs is overall favorable, many patients experience resistance to chemotherapy, relapse and/or long term adverse health effects following treatment. Targeted therapies, based on integrated analyses of molecular tumor data such as that presented here, may provide a way to secure high cure rates while reducing unintended health consequences
Availability note (English)
Available from http://dx.doi.org/10.1186/s12885-015-1796-6; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619074Additional details
Identifiers
Publishing Information
- Journal Title
- BMC cancer (Online)
- Journal Volume
- 15
- Journal Page Range
- vp.
- ISSN
- 1471-2407
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 47084315
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ANIMAL TISSUES; CHEMOTHERAPY; GERM CELLS; HISTOLOGY; METHYLATION; NEOPLASMS; STEM CELLS; TRANSCRIPTION FACTORS
- Descriptors DEC
- ANIMAL CELLS; BODY; CHEMICAL REACTIONS; DISEASES; MEDICINE; ORGANIC COMPOUNDS; PROTEINS; SOMATIC CELLS; THERAPY
Optional Information
- Copyright
- Copyright (c) Poynter et al. 2015
- Notes
- PMCID: PMC4619074; PMID: 26497383; PUBLISHER-ID: 1796; OAI: oai:pubmedcentral.nih.gov:4619074